Albert Bourla is Pfizer’s chairman and chief executive officer. He became CEO in January 2019 and chairman in January 2020. Pfizer reported $62.6 billion in revenue for 2025; the title’s $203.63 billion figure is not identified in the reviewed official sources by metric or date, so it should not be read as annual revenue.
Who is Albert Bourla?
Bourla is the leader of Pfizer, the U.S.-based pharmaceutical company. Pfizer’s leadership biography says he leads the company in its stated purpose, “Breakthroughs that change patients’ lives,” and describes its focus as oncology, internal medicine, inflammation and immunology, and vaccines. These are Pfizer’s descriptions of its priorities and purpose.
Before becoming CEO, Bourla served as Pfizer’s chief operating officer from January through December 2018. He was Group President of Pfizer Innovative Health from June 2016 through December 2017. Pfizer’s 2025 Form 10-K says he has been CEO since January 2019 and chairman since January 2020.
What does Pfizer’s $203.63 billion figure mean?
The reviewed official sources do not establish what the $203.63 billion figure measures or when it was measured. It is not Pfizer’s reported 2025 annual revenue. Annual revenue is the money a company reports from its business over a period; market capitalization is a valuation based on its share price and shares outstanding. They are different measures, and the title’s figure cannot be assigned to either on the evidence available here.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
#1 Best Overall
How much revenue did Pfizer report?
Pfizer’s 2025 annual review reports revenue of $62.6 billion for the year, down from $63.6 billion in 2024. The company characterized the 2025 change as a 2% operational decline. Excluding COVID-19 products, Pfizer reported 6% operational revenue growth. These are Pfizer-reported figures, not a forecast or a market-value estimate.
Pfizer’s annual review lists its three highest-revenue products in 2025 as Eliquis at $7,961 million, the Prevnar family at $6,494 million, and the Vyndaqel family at $6,380 million. These are product revenues reported by Pfizer for 2025.
Rank #2
What is Pfizer working on under Bourla?
Pfizer identifies oncology, internal medicine, inflammation and immunology, and vaccines as strategic areas. The company says its 2023 acquisition of Seagen advanced its oncology pipeline, while its 2025 acquisition of Metsera expanded its presence in obesity and metabolic disease. Those descriptions reflect Pfizer’s account of its strategy and acquisitions.
In its 2026 proxy statement, Pfizer said it reached more than 448 million patients globally with medicines and vaccines in 2025. The same statement reported four key approvals across the U.S. and EU, eight key positive Phase 3 readouts, and 11 pivotal study starts during 2025. These are company-reported activity and reach measures, not independently verified measures of health outcomes.
Rank #3
What is Bourla’s book about?
Bourla wrote Moonshot: Inside Pfizer’s Nine-Month Race to Make the Impossible Possible, a first-person account of Pfizer’s effort to develop a COVID-19 vaccine. The publisher describes it as a behind-the-scenes account, so it is best understood as Bourla’s perspective rather than independent corroboration of the events. Bourla’s book, Moonshot, is listed by its publisher with an Amazon ordering path.
Pfizer’s page about the book says proceeds from book sales will be donated to charity; that is the company’s statement, not an independently verified accounting of proceeds. In reflecting on the book, Bourla credited colleagues, partners, stakeholders, and clinical-trial volunteers for the work it describes.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
